Lymphatic endothelial cells are active regulators of immune tolerance rather than passive conduits. Research shows that lymphatic endothelial cells (LECs) can archive and present self-derived peptides, express immunoregulatory ligands, and shape the cellular context in which T cells encounter antigen. These activities contribute to the deletion or functional inactivation of self-reactive lymphocytes and therefore to long-term peripheral tolerance.
Mechanisms of antigen handling and presentation
LECs acquire self-antigens from tissues and the lymph and can present peptides on class I major histocompatibility complex molecules to CD8 T cells. Work from Shannon K. Turley at Memorial Sloan Kettering Cancer Center indicates that LECs express a spectrum of peripheral tissue antigens and promote deletional tolerance of CD8 T cells through antigen presentation combined with high expression of the inhibitory ligand PD-L1. In addition, studies by Melody Swartz at École Polytechnique Fédérale de Lausanne emphasize how lymphatic vessels control antigen flow and immune cell trafficking, affecting the likelihood that dendritic cells and T cells will meet and respond. These processes are context-dependent: in steady state LEC signaling favors tolerance, whereas inflammation can transiently alter antigen transfer and costimulatory environments.
Regulatory signals and microenvironmental context
Beyond peptide display, LECs secrete chemokines such as CCL21 that direct cell positioning within lymph nodes and modulate encounters between antigen-presenting cells and naïve T cells. LECs also express molecules that dampen T cell activation, including PD-L1 and indoleamine 2,3-dioxygenase in certain contexts, promoting anergy or deletion rather than effector differentiation. Antigen transfer from LECs to professional antigen-presenting cells can further reinforce tolerogenic outcomes by providing peptide in a noninflammatory context. Collectively, these mechanisms reduce the survival or effector conversion of self-reactive clones.
The relevance is practical: defects in lymphatic architecture or LEC function can tilt the balance toward autoimmunity, while tumors may exploit LEC-mediated tolerance to evade immune detection. Human and territorial nuances matter because lymphatic density, inflammatory exposure, and genetic background influence how strongly LEC-mediated tolerance operates in different tissues and populations. Understanding LEC roles offers pathways for therapies that restore tolerance in autoimmune disease or, conversely, block tolerance in cancer immunotherapy, guided by mechanistic studies from established labs and institutions.